Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Biopsy Clear all
Completed Phase 2 Interventional Results available

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

NCT01672853
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
Simtuzumab, Placebo
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting No phase listed Observational

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

NCT07303712
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Not listed
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)

NCT03245580
View directory record Official record
Conditions
Liver Diseases
Interventions
Core Liver Biopsy
Diagnostic Test
Lead sponsor
Parkview Health
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Mobile, Alabama • San Jose, California • Fort Wayne, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

NCT04965454
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
Fluorine-18 fluorocholine
Combination Product
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Pioglitazone to Treat Fatty Liver in People With HIV Infection

NCT00441272
View directory record Official record
Conditions
HIV Infections, Hepatic Steatosis, Insulin Resistance
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

NCT01598987
View directory record Official record
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn Not applicable Interventional

Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures.

NCT05790109
View directory record Official record
Conditions
Bleeding Disorder, Spleen Lesion, Liver Diseases, Kidney Diseases
Interventions
RF track cautery during percutaneous organ biopsy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ultrasound Based Acoustic Radiation Force Impulse Imaging

NCT01781208
View directory record Official record
Conditions
Liver Fibrosis, Liver Inflammation
Interventions
Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)
Device
Lead sponsor
University of Michigan
Other
Eligibility
Up to 18 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

NCT00326482
View directory record Official record
Conditions
Liver Fibrosis, Steatohepatitis, Elevated Transaminases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT04906421
View directory record Official record
Conditions
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Interventions
TVB-2640, Placebo
Drug · Other
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
103
States / cities
Huntsville, Alabama • Madison, Alabama • Sun City, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures

NCT05593211
View directory record Official record
Conditions
Hepatic Disease, Renal Disease
Interventions
Kronos Electrocautery Device
Device
Lead sponsor
Single Pass Inc
Industry
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

NCT06920043
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

NCT02124044
View directory record Official record
Conditions
HIV-HCV
Interventions
Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 4, 2026, 4:15 AM EDT
Not yet recruiting No phase listed Observational

Liver Biopsy Following Gene Therapy For Hemophilia

NCT05932914
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Liver Biopsy
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Lamivudine and Adefovir to Treat Chronic Hepatitis B

NCT00023309
View directory record Official record
Conditions
HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
Interventions
Lamivudine and adefovir, Adefovir alone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 4, 2026, 4:15 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

NCT01783314
View directory record Official record
Conditions
Hepatic Fibrosis
Interventions
MRI of liver
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational

A Controlled Prospective Study of Transfusion-Associated Hepatitis

NCT00004848
View directory record Official record
Conditions
Hepatitis
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1981 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

NCT04378010
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 1.5 mg, EDP-305 2 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
68
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

NCT04929483
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
BIO89-100, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional

19Gauge Fine Needle Biopsy (FNB) Versus 22Gauge FNB for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB)

NCT04806607
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
19G FNB, 22G FNB
Procedure
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Wet Heparinized Suction for Abdominal Cancer

NCT05041335
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Stomach, Cancer of Esophagus, Cancer of Liver, Cancer
Interventions
wet heparinzed suction, Microsieve, No heparin flush, No microsieve
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting No phase listed Observational

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

NCT06342414
View directory record Official record
Conditions
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer, Primary Liver Carcinoma, Hepatic Cancer, Hepatic Carcinoma
Interventions
ELUCIDATE
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Liver Biopsy Using a 19 Gauge Fine Needle Biopsy Needle

NCT03910790
View directory record Official record
Conditions
Liver Biopsy
Interventions
19 gauge needle liver biopsy
Device
Lead sponsor
AdventHealth
Other
Eligibility
19 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 4, 2026, 4:15 AM EDT